Bölümler
-
In this episode of Life Science Success, host Don interviews Dr. Sam Clark, founder and CEO of Terran Biosciences. They talk about Dr. Clark's innovative approach to creating new neuropsychiatric therapeutics and how his personal experiences with mental illness inspired him to enter the biotech industry. The episode also explores various breakthroughs at Terran, including their innovative work with prodrugs, anti-psychotics, and psychedelics, along with their unique, efficient team structure modeled after Silicon Valley tech companies. Additionally, they delve into the inspiration, challenges, and methodologies that drive Terran's mission to provide affordable and modern treatments for patients in need. 00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message from D3 Digital Media Marketing 01:21 Guest Introduction: Dr. Sam Clark 02:12 Dr. Clark's Journey into Biotech 04:15 Founding Terran Biosciences 07:13 Innovative Projects at Terran 13:00 Psychedelic Compounds and Patient Use 20:00 Overcoming Barriers in Drug Development 23:57 Leadership and Inspiration 31:09 Conclusion and Final Thoughts
-
In this episode of Life Science Success, host Don interviews Vance Lyon, an accomplished chemist with a four-decade career in the life sciences industry. Vance discusses his educational background, career journey, and key experiences. The conversation also delves into the vital role of Davos Pharma in providing comprehensive services for biotech companies, including API production, formulation, and IND filings. Vance shares insights on leadership, his inspirations, and concerns, while reflecting on his contributions to significant pharmaceutical projects. Join us for an engaging discussion on life sciences, chemistry, and the intricacies of pharmaceutical development. 00:00 Introduction to Life Science Success Podcast 00:39 Sponsor Message: D3 Digital Media Marketing 01:22 Meet Vance Lyon: A Journey in Chemistry 02:27 Early Life and Education 07:22 Career Beginnings at Parish Chemical 11:08 Transition to Kemmerer Polytech 12:57 Joining Davos and Key Projects 16:06 Services Provided by Davos 27:34 Leadership and Personal Insights 35:52 Conclusion and Farewell
-
Eksik bölüm mü var?
-
In this episode of the Life Science Success Podcast, host Don Davis, PhD, MBA, interviews Dr. William Chou of Passage Bio. Dr. Chou discusses his transition from a practicing physician to a leader in biotechnology, reflects on the profound patient relationships he misses, and shares insights into Passage Bio's work on gene therapy for neurodegenerative diseases like Frontotemporal Dementia (FTD). They delve into the progress of their Phase 1/2 clinical study, the urgency of developing treatments for genetic mutations, and the potential impact on patients and their families. Learn about the most recent developments and how Passage Bio is working to give those suffering from these life-threatening conditions hope. 00:00 Welcome and Introduction 00:25 William's Journey into Life Sciences 01:30 The Emotional Impact of Leaving Clinical Practice 02:31 Overview of Passage Bio 02:52 Understanding Frontotemporal Dementia (FTD) 06:38 Current Progress and Future Prospects 10:04 The Urgency and Hope for FTD Treatments 11:37 Goals and Closing Remarks
-
In this episode of the Life Science Success Podcast, Don Davis PhD, MBA interviews Igor Fisch, founder of NewBiologix. Igor shares his journey from academia to entrepreneurship, highlighting his success with Selexis, a company he sold in 2017 that specialized in monoclonal antibodies. He discusses the challenges of gene therapy, specifically the high costs, and NewBiologix's innovative approach to making gene therapy more affordable. Igor also provides insights into the industry's future, emphasizing the significance of stable production platforms for viral particles.
00:00 Introduction and Welcome
00:15 Igor's Journey into Life Sciences
00:37 The Success of Selexis
00:56 Transition to Gene Therapy
03:32 Challenges in Gene Therapy
03:50 The Importance of Stable Platforms
05:11 The Role of Biotech Startups
05:57 Balancing Science and Business
06:51 Networking at BIO Conference
08:14 Future Vision for New Biologics
09:21 Conclusion and Farewell
-
In this episode of the Life Science Success Podcast, Dean Petkanas, co-founder of Kannalife Sciences, is interviewed at the Bio International Convention in San Diego. Dean shares his journey from investment banking in the 80s to founding Kannalife Sciences in 2009. He discusses the company's focus on developing cannabinoid-based drugs, specifically targeting chemotherapy-induced peripheral neuropathy. The conversation covers the challenges and opportunities in cannabinoid drug development, the importance of targeting specific types of pain, and the current state and future prospects of Kannalife Sciences. Dean also highlights the significance of partnering and collaboration in advancing novel therapeutics. 00:00 Welcome to the Life Science Success Podcast 00:20 Dean's Journey into Life Sciences 01:04 The Evolution of Kannalife Sciences 02:18 Challenges and Opportunities in Cannabinoid-Based Drugs 03:06 Understanding Pain and Neuropathy 06:08 Investment Insights and Market Trends 07:40 Kannalife Sciences's Current Focus and Future Prospects 10:02 The Importance of Partnering at Bio 11:02 Closing Remarks and Future Meetings
-
In this episode of the Life Science Success Podcast, host Don interviews Sean Rothwell, CEO of Evoke Nano, about the company's groundbreaking work in developing EBQ218, a revolutionary nanoparticle-based pulmonary therapeutic. They discuss the efficacy of EBQ218 in treating cystic fibrosis and its potential as a broad-spectrum antibiotic against drug-resistant superbugs. Sean shares insights into the company's journey, their upcoming clinical trials, and the broader impact of their work on patient outcomes in the healthcare landscape. Tune in to learn how Evoke Bio is poised to make a significant difference in combating infectious diseases and improving lives. 00:00 Welcome and Introduction 00:09 First Impressions of BIO Conference 00:37 Sean's Background and Journey into Life Sciences 01:42 The Science Behind Evoke Nano 02:28 EBQ218: A Revolutionary Pulmonary Therapeutic 04:16 Challenges and Future Pathways 05:24 Investment and Partnership Opportunities 06:42 Broader Applications and Future Vision 08:16 Addressing Drug Resistance and Regulatory Pathways 18:48 Conclusion and Final Thoughts
-
This is the second part of the interview where, with Maruiano, we will discuss more of the technology and development for Elem Biotech.
In this episode of the Life Science Success Podcast, Don Davis discusses the BIO conference and the future of biomedical research with Mauriano Vázquez. They delve into the significance of networking events, the evolution of computing capabilities, advanced simulation codes, and the potential applications of AI and quantum computing in life sciences. Mauriano shares his unique journey from Argentina to becoming a physicist specializing in computational mechanics, and how his work in cardiac electrophysiology can significantly impact patient care. The conversation wraps up with insights into the future use of virtual and augmented reality in medical applications. 00:00 Introduction and Conference Impressions 02:37 Mariano's Background and Journey into Life Sciences 06:22 Applications of Simulation Technology 10:48 Evolution of Computing Capabilities 13:37 Future of AI and Quantum Computing 14:41 Virtual Reality in Medical Applications 19:40 Conclusion and Final Thoughts -
There are two parts of this interview, in the first session, I dive into Elem and what the company is doing with Christopher Morton.
In this exciting episode of Life Science Discussed Podcast, host Don Davis welcomes Christopher Morton, CEO of Elem Biotech, to talk about the groundbreaking work of virtual human twins in drug and medical device testing. Morton, an aeronautical engineer turned biotech innovator, discusses Elem's platform that allows pharmaceutical companies, medtechs, and CROs to test new therapeutics using virtual human models instead of animal models. They delve into how this approach, distinct from AI-based methods, focuses on mechanistic modeling using MRIs and CT scans to replicate human physiological functions. Morton explains how Elem Biotech's solutions help in precision medicine, clinical trial design, and reducing animal trials, supported by supercomputing power and cloud technology. Tune in to discover how virtual human models are poised to transform life sciences and medical testing. 00:00 Introduction and Welcome 00:43 Christopher Morton's Background 01:57 Introduction to Elem Biotech 02:45 Mechanistic Approach vs. AI Models 03:47 Precision Medicine and Virtual Human Twins 08:58 Supercomputing and Technological Infrastructure 13:07 Applications in Pharma and Medical Devices 21:07 Challenges and Future Directions 25:59 Conclusion and Final Thoughts -
In this episode of the Lifescience Success Podcast, host Don Davis interviews James Hackworth, who shares insights about his background in physics and his journey into the life science industry. James discusses his experiences from McKinsey up to his current role at Tris Pharma, focusing on their innovative drug development and formulation technologies. He dives into the company's advancements in ADHD medications and an exciting new pain management drugs. Additionally, the conversation highlights the importance of partnerships, technology in drug development, and future industry trends. James provides a fascinating glimpse into the complexities and future of pharmaceuticals.
00:00 Welcome and Introduction
00:08 Impressions of the Bio Conference
00:42 James' Background and Journey into Pharma
03:17 Formation and Growth of Park Therapeutics
04:20 Overview of Tris Pharma
04:41 Tris Pharma's Focus and Innovations
08:00 Challenges and Opportunities in Partnering
10:58 Future of Tris Pharma and the Industry
15:41 In-depth Look at Drugs that are progressing
19:21 Conclusion and Final Thoughts -
In this episode of the Life Science Success Podcast, Don interviews Himanshu Gadgil from Enzine during Bio International. Himanshu explains Enzine’s dual focus on developing biosimilars and their role as a CDMO with a game-changing platform, Enzine X. They discuss how Enzine's continuous manufacturing technology significantly cuts costs and speeds up market access for clients. Himanshu also talks about Enzine’s global presence, clientele, and their future plans for expansion in the U.S. and India. Tune in to learn about the innovative approaches Enzine is bringing to the biotech industry. 00:00 Welcome and Introduction 00:07 Overview of Enzine Biotech 00:26 Enzine's Unique Manufacturing Platform 01:08 Clientele and Market Reach 01:41 Timelines and Efficiency 02:08 Future of Continuous Manufacturing 04:22 Geographical Expansion and Workforce 05:02 Enzine's Differentiators 06:10 Conclusion and Final Thoughts
-
Join us on the Life Science Success Podcast as we delve into the fascinating journey of Andy Mehrotra, a pharmacist turned entrepreneur, who pioneered Unipr, an AI and machine learning platform aimed at addressing inefficiencies in drug development. Learn about his transition from sales and marketing to leading an innovative company, the significance of integrating and unifying data, and how Unipr is reshaping the pharmaceutical industry. Discover how Unipr is not just a solution for the life sciences but a model for other complex industries. Listen in for insights on the future of collaborative technology and its potential to accelerate health innovations. 00:00 Introduction and Guest Welcome 00:06 Guest Background and Career Journey 01:19 Transition to Leadership 02:29 Pharmaceutical Industry Insights 06:00 Introduction to Unipr 06:08 Uniper's Technology and Solutions 08:56 Client Use Cases and Success Stories 12:37 Integration vs. Unification 17:23 Conference Goals and Future Vision 21:41 Conclusion and Final Thoughts
-
Welcome to the Life Science Success Podcast! In this episode, host Don interviews Catherine from Jellox Biotech at Bio Interntional June of 2024. Catherine shares insights into her journey from financial engineering to the life sciences field, her experience in investment banking, and her current role in business development at Jellox Biotech. She discusses Jellox Biotech's groundbreaking 3D imaging technology for digital pathology, its benefits for early cancer diagnosis, and the company's expansion plans. Catherine also sheds light on the challenges and hopes for the future, especially regarding raising venture capital and global outreach. 00:00 Introduction and Guest Welcome 00:07 Catherine's Background and Career Journey 00:43 Introduction to Jellox Biotech 01:11 Innovations in 3D Imaging and Digital Pathology 02:22 Product Development and Market Expansion 03:56 Challenges and Goals at Bio Conference 08:06 Global Expansion Plans 09:37 Future Aspirations and Technological Impact 15:39 Conclusion and Farewell
-
In this episode of the Life Science Success podcast, we have Dr. David E. Martin, the President and CEO of TrippBio, Inc., a distinguished translational scientist with over 30 years of experience in drug development. Dr. Martin has led numerous groundbreaking projects and is here to share his insights on the future of therapeutic advancements.
🚀 Book a FREE Digital Marketing strategy Session 👉 https://link.cxnector.com/widget/book...
Introduction of Dr. David E. Martin: Dr. David E. Martin, with over 30 years in drug development, joins Don on the "Life Science Success" podcast to discuss his career and insights into therapeutic advancements.
Dr. Martin's Background: Dr. Martin, trained as a pharmacist during the AIDS epidemic, developed a passion for infectious diseases and clinical research, which led him into life sciences. His career is marked by his role as a translational scientist focusing on groundbreaking projects.
Professional Achievements: He highlights his work with HIV RNA as a surrogate marker in drug development, detailing his involvement in pioneering studies that validated PCR technology in clinical trials. This work significantly contributed to how drug efficacy is evaluated, particularly concerning HIV treatments.
Role at TrippBio: As the CEO of TrippBio, Dr. Martin discusses the company's focus on developing drugs targeting host factors rather than the pathogens themselves, reducing the likelihood of resistance. TrippBio is exploring treatments for major respiratory viruses using this novel approach.
Vision and Challenges: Dr. Martin shares his vision for TrippBio to develop a universal treatment for major respiratory infections and discusses the challenges small biotechs face, especially in securing funding and managing innovative research within tight budgets.
-
In this episode of Life Science Success, host Don Davis PhD, MBA, a digital marketer in life sciences, interviews Sabrina Johnson, CEO, and founder of DARE Bioscience. With a passion for advancing women's healthcare, Sabrina shares her career path from biochemical engineering to founding DARE Bioscience. She discusses the inception of the company, its innovative pipeline, including non-hormonal contraceptives and treatments for female arousal disorder, and the unique challenges they faced, like funding and public awareness. Sabrina emphasizes the importance of addressing unmet needs in women’s health, the strategic decisions behind their reverse merger, and her optimistic vision for the future of women's health treatments.
Key Takeaways Purpose-Driven Innovation: Daré Bioscience was founded to address significant gaps in women's healthcare, driven by Sabrina Johnson's commitment to making a difference in areas with unmet needs. Strategic Funding: Opting for a public company model allowed Daré Bioscience to secure necessary funding for its extensive product pipeline. Collaborative Development: Partnering with established companies like Bayer helps in the commercialization and broader reach of innovative products. Focus on Unmet Needs: The company's approach starts with identifying specific unmet needs in women's health, ensuring their products address significant issues. Leadership and Authenticity: Sabrina Johnson highlights the importance of authentic leadership, problem-solving, and not shying away from challenges to drive innovation and success in healthcare. -
In this episode of the Life Science Success Podcast, host Don Davis interviews Christian Engstrom, CEO of Bullpen, an elite club focused on fostering collaborative success in the life sciences industry. They discuss Christian's background, his motivation for creating Bullpen, the club's mission to help entrepreneurs and investors connect and support each other, and the various success stories stemming from Bullpen's initiatives. They also delve into upcoming events at the BIO International Convention and the club's future direction. Christian emphasizes the power of authentic networking and resource sharing among life sciences professionals.
Key Takeaways:
Collaborative Environment: Bullpen Ventures fosters a collaborative environment where members can network and support each other, addressing gaps in the life sciences sector.
Event Organization: Bullpen organizes unique, engaging events at major conferences to facilitate networking and partnerships among life science professionals.
Philosophical Approach: The club operates on mutual support, humility, and leveraging each member's strengths to create a supportive and effective community.
Non-Profit Focus: Bullpen emphasizes non-profit collaboration and relies on sponsor partners to cover costs, ensuring that resources are directed towards helping entrepreneurs and small businesses.
Future Vision: Bullpen aims to be a hub for DEI initiatives and a power center for collaboration, with a focus on aligning with partners who share their values and contribute to the community's success.
-
In this episode, we sit down with Aron Knickerbocker, President and CEO of Aulos Bioscience. Aron shares his extensive experience in the Life Sciences industry, highlighting his pivotal roles at RayzeBio, Five Prime Therapeutics, and Genentech. He discusses Aulos’ innovative approaches to cancer treatment, particularly in radiopharmaceuticals and targeted therapies. Aron also reflects on the key leadership advice that has shaped his career and shares his insights on the future of oncology. Tune in to learn about the groundbreaking work at Aulos and Aron’s vision for advancing cancer treatment.
Personal Motivation: Aron’s dedication to cancer treatment is deeply personal, influenced by his mother’s death from cancer. Innovative Approaches: Aulos Biosciences uses immune system engagement instead of traditional radiotherapy, showing promise in early trials. Diverse Experience: Aron’s career spans research, business development, and leadership roles, providing a comprehensive understanding of the biotech industry. Leadership Values: Effective decision-making, scientific rigor, and a strong team are central to Aron’s leadership style. Future Vision: Aron envisions AU-007 making a significant impact on cancer treatment, with aspirations of achieving groundbreaking results in clinical trials. https://www.lifesciencesuccess.com/pauledwards/ -
Paul Edwards is the President and CEO of DoseMeRx. He has been a Senior Executive with Merck and GSK, and start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has an extensive history in infectious disease, antimicrobial stewardship, and precision medicine.
Guest Introduction: Paul Edwards, the President and CEO of DoseMeRx, shares his extensive background in the pharmaceutical industry, including roles at Merck, GSK, and various startups, focusing on antibiotics and infectious diseases.
Pharmaceutical Journey: Paul discusses his career progression from selling macrolides to leading infectious disease units and moving to the U.S. to transform commercial models at Merck, emphasizing the importance of real-world data over clinical trial data.
DoseMeRx Focus: DoseMeRx specializes in precise dosing for critically ill patients using therapeutic drug monitoring, particularly for injectable antibiotics, aiming to provide accurate dosing information through web-based and integrated models within hospital systems.
Challenges and Future of Medicine: Paul highlights the importance of antimicrobial stewardship, pharmacogenomics, and personalized medicine in improving patient care and expresses concerns about the current insurance and payment systems based on actuarial science.
-
In this episode of the Life Science Success Podcast, I am joined by Dr. Rafael G.
Amado, an esteemed leader in oncology research and development, currently serving as
the President and Head of Global Oncology at Zai Lab. With a distinguished career
spanning multiple leading biotech firms, Dr. Amado brings a wealth of experience in
gene-engineered cell therapies and innovative cancer treatments.Professional Background: Dr. Rafael G. Amado is currently the president and head of global oncology at Zai Lab. He has a rich background in medicine, starting with his education in Spain, followed by a move to the U.S. where he specialized in Internal Medicine and later Hematology Oncology at the University of California, Los Angeles.
Passion for Oncology: Dr. Amado's interest in oncology stems from its complex nature and the multifaceted approach it requires, combining diagnostics, therapeutics, and a detective-like inquiry into patient cases. His career shift towards oncology was influenced by its holistic approach to patient care and his personal drive to solve complex medical puzzles.
Research and Development Focus: At Zai Lab, Dr. Amado oversees oncology research and development, focusing on gene-engineered cell therapies among other innovative treatments. He has been involved in significant breakthroughs, such as determining drug inefficacies in patients with certain genetic mutations, which has influenced global regulatory changes in cancer treatment.
Corporate and Global Strategy: Under Dr. Amado’s leadership, Zai Lab has approved six drugs in China, with a strong emphasis on addressing grievous illnesses through open innovation. He is instrumental in expanding the company's global reach, aiming to impact a broad patient base internationally by aligning clinical trials and regulatory strategies across diverse geographic locations.
Vision and Future Goals: Dr. Amado is committed to advancing drug development that significantly outweighs potential risks with therapeutic benefits. He is driven by a mission to impact oncology treatment on a global scale, with ambitious goals to reach approximately a million patients by 2030 through continuous innovation and strategic drug development.
-
This week on the Life Science Success Podcast my guest is Dan Lunz. Dan Lunz is the CEO and Co-founder of Previse, a pioneering company based in Baltimore, Maryland, that specializes in offering tests for the prediction and earlier detection of upper-GI cancers.
Background of Dan Lunz: Dan Lunz, CEO and co-founder of Previse, shares his journey from growing up in Baltimore, serving in the Marine Corps, experiencing healthcare firsthand as a patient in the VA system, to studying at Johns Hopkins and working in clinical research. His career path was significantly influenced by his desire to serve others, leading him to the life sciences sector.
Formation of Previse: Lunz's collaboration with Dr. Steven Meltzer, a professor at Johns Hopkins, sparked the founding of Previse. They focused on developing diagnostic tools for early detection of upper GI cancers based on Meltzer's research on biomarkers. Their shared mission was to improve patient outcomes through innovative medical technologies.
Previse's Diagnostic Innovations: Previse specializes in detecting and predicting upper gastrointestinal (GI) cancers. The company offers a commercial test called ESO Predict, which assesses the risk of esophageal cancer in patients with conditions like Barrett's esophagus, helping physicians strategize patient management and surveillance intervals.
Challenges and Leadership Insights: Throughout the interview, Lunz discusses the entrepreneurial challenges of securing funding and navigating regulatory landscapes. He emphasizes the importance of perseverance and humility in leadership, learning from rejections, and the critical role of assembling a talented team to overcome complex challenges.
Future Goals and Impact: Looking forward, Previse aims to expand access to its existing diagnostics across the U.S. and continue developing non-endoscopic tools and medical devices to enhance GI cancer detection. Lunz is driven by the potential impact of their technology in preventing cancer and improving patient care, underscoring his dedication to service and innovation in life sciences.
-
In this episode of the Life Science Success Podcast our guest is Leonard Mazur, CEO and Co-Founder of Citius Pharmaceuticals. With over 50 years of experience in the biopharma industry, Leonard has been at the forefront of developing groundbreaking therapies for patients with unmet medical needs.
Background and Entry into Biopharmaceuticals: Leonard Mazur, CEO and co-founder of Citius Pharmaceuticals, began his career through an unexpected newspaper ad, leading him to pharmaceutical sales. His liberal arts background as a psychology major did not initially suggest a career in biopharma, highlighting the unpredictability of career paths.
Early Career Development: Mazur's rapid career advancement occurred within Cooper Laboratories, an entrepreneurial company where he transitioned from sales to marketing and strategic planning. This period involved substantial growth through acquisitions, providing him with a broad range of experiences in the pharmaceutical sector.
Entrepreneurial Ventures: Throughout his career, Leonard Mazur has initiated multiple entrepreneurial efforts, ultimately leading to the founding of Citius Pharmaceuticals. His story is marked by significant risk-taking, including personal financial stakes in business initiatives, reflecting his deep commitment to his entrepreneurial pursuits.
Focus of Citius Pharmaceuticals: Citius Pharmaceuticals, which Mazur co-founded, is dedicated to developing innovative treatments for critical care. A key product from Citius is an antibiotic lock solution for treating infections in central venous catheters, illustrating the company's commitment to addressing complex medical needs.
Views on Industry and Innovation: Mazur discusses the critical role of the biopharmaceutical industry in global drug development, emphasizing the potential risks to innovation from policy changes such as the implementation of socialized medicine. His insights reflect on the industry's dynamics and the importance of sustaining an environment conducive to pharmaceutical innovation.
- Daha fazla göster
